Alaunos Therapeutics (TCRT) Retained Earnings (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Retained Earnings came in at -$925.6 million in Q1 2026, little changed YoY from -$929.8 million in Q1 2025, and little changed on a QoQ basis from -$924.6 million in Q4 2025.
Alaunos Therapeutics (TCRT) Retained Earnings (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Retained Earnings data on file, last reported at -$925.6 million in Q1 2026.
- Quarterly Retained Earnings changed 0.45% year-over-year to -$925.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$925.6 million (changed 0.45% YoY) and the FY2025 annual result came in at -$924.6 million, changed 0.45% from the prior year.
- Retained Earnings held at -$925.6 million in Q1 2026, from -$924.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$852.6 million in Q1 2022 to a low of -$925.6 million in Q1 2026.
- A 5-year average of -$904.5 million and a median of -$918.6 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings fell 8.53% — and 2025, when it dropped 0.28%.
- Tracing TCRT's Retained Earnings over 5 years: stood at -$880.6 million in 2022, then decreased by 3.99% to -$915.8 million in 2023, then decreased by 0.51% to -$920.4 million in 2024, then dropped by 0.45% to -$924.6 million in 2025, then declined by 0.11% to -$925.6 million in 2026.
- The last three Retained Earnings figures came in at -$925.6 million (Q1 2026), -$924.6 million (Q4 2025), and -$923.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -926.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -925.63 Mn |
| Dec 31, 2025 | -924.62 Mn |
| Sep 30, 2025 | -923.70 Mn |
| Jun 30, 2025 | -922.60 Mn |
| Mar 31, 2025 | -921.50 Mn |
| Dec 31, 2024 | -920.45 Mn |
| Sep 30, 2024 | -919.70 Mn |
| Jun 30, 2024 | -918.58 Mn |
| Mar 31, 2024 | -918.90 Mn |
| Dec 31, 2023 | -915.77 Mn |
| Sep 30, 2023 | -907.90 Mn |
| Jun 30, 2023 | -899.40 Mn |
| Mar 31, 2023 | -890.68 Mn |
| Dec 31, 2022 | -880.63 Mn |
| Sep 30, 2022 | -871.47 Mn |
| Jun 30, 2022 | -862.57 Mn |
| Mar 31, 2022 | -852.64 Mn |
| Dec 31, 2021 | -842.85 Mn |
| Sep 30, 2021 | -831.10 Mn |
| Jun 30, 2021 | -808.33 Mn |